Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • All Public Company
      • English-only
      • News Releases Overview

      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
      • Multimedia Gallery Overview

      • Trending Topics

      • All Trending Topics
  • Business & Money
      • Auto & Transportation

      • All Automotive & Transportation
      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • Auto & Transportation Overview

      • View All Auto & Transportation

      • Business Technology

      • All Business Technology
      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • Business Technology Overview

      • View All Business Technology

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Financial Services & Investing

      • All Financial Services & Investing
      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • Financial Services & Investing Overview

      • View All Financial Services & Investing

      • General Business

      • All General Business
      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • General Business Overview

      • View All General Business

  • Science & Tech
      • Consumer Technology

      • All Consumer Technology
      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • Consumer Technology Overview

      • View All Consumer Technology

      • Energy & Natural Resources

      • All Energy
      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • Energy & Natural Resources Overview

      • View All Energy & Natural Resources

      • Environ­ment

      • All Environ­ment
      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • Environ­ment Overview

      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • All Heavy Industry & Manufacturing
      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • Heavy Industry & Manufacturing Overview

      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • All Telecomm­unications
      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • Telecomm­unications Overview

      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • All Consumer Products & Retail
      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • Consumer Products & Retail Overview

      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • All Entertain­ment & Media
      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • Entertain­ment & Media Overview

      • View All Entertain­ment & Media

      • Health

      • All Health
      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • Health Overview

      • View All Health

      • Sports

      • All Sports
      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • Sports Overview

      • View All Sports

      • Travel

      • All Travel
      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • Travel Overview

      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • All Policy & Public Interest
      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • Policy & Public Interest Overview

      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • All People & Culture
      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • People & Culture Overview

      • View All People & Culture

      • In-Language News

      • Arabic
      • español
      • português
      • Česko
      • Danmark
      • Deutschland
      • España
      • France
      • Italia
      • Nederland
      • Norge
      • Polska
      • Portugal
      • Россия
      • Slovensko
      • Suomi
      • Sverige
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Hamburger menu
  • PR Newswire: news distribution, targeting and monitoring
  • Send a Release
    • ALL CONTACT INFO
    • Contact Us

      888-776-0942
      from 8 AM - 10 PM ET

  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • News in Focus
    • Browse All News
    • Multimedia Gallery
    • Trending Topics
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • Explore Our Platform
  • Plan Campaigns
  • Create with AI
  • Distribute Press Releases
  • Amplify Content
  • All Products
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices
  • Send a Release
  • Client Login
  • Resources
  • Blog
  • Journalists
  • RSS

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP, 25 mg, 50 mg and 100 mg Due to the Detection of Trace Amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) Impurity found in the Active Pharmaceutical Ingredient (API)


News provided by

Camber Pharmaceuticals

Feb 28, 2019, 12:39 ET

Share this article

Share toX

Share this article

Share toX

PISCATAWAY, N.J., Feb. 28, 2019 /PRNewswire/ --

Company Contact: Stericycle
Name: Stericycle Customer Service – Recalls – Event 4862
Phone Number: 1-888-275-0506
Email: [email protected]

Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted due to the detection of trace amounts of N-Nitroso N-Methyl 4-amino butyric acid (NMBA) a possible process impurity or contaminant in an active pharmaceutical ingredient, manufactured by Hetero Labs Limited, Unit – I (API manufacturer).

NMBA is a potential human carcinogen. To date, Camber has not received any reports of adverse events related to this recall.  

Losartan Potassium, USP, is a prescription medication used to treat high blood pressure and congestive heart failure and is packaged in 30ct, 90ct, 500ct, 1000ct bottles. The identifying NDC #s associated with Camber's product as are follows: Losartan 25 mg 31722-700-90, 31722-700-05, 31722-700-10; Losartan 50 mg 31722-701-30, 31722-701-90, 31722-701-10; and Losartan 100 mg 31722-702-30, 31722-702-90, and 31722-702-10.

The affected Losartan includes 87 lot numbers which are listed below:

NDC

Name and Strength

Count

Lot#

Expiry

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP17026B

Sep-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP17050

Sep-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP17051

Sep-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP17052

Sep-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP17053

Sep-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP17061

Oct-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP18035

Dec-19

31722-700-90

Losartan Potassium Tablets USP 25 mg

90

LOP18036

Dec-19

31722-700-05

Losartan Potassium Tablets USP 25 mg

500

LOP17026

Sep-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP17006

May-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP17025

Sep-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP17068

Oct-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP18037

Dec-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP18038

Dec-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP18039

Dec-19

31722-700-10

Losartan Potassium Tablets USP 25 mg

1000

LOP18057

Jan-20

31722-701-30

Losartan Potassium Tablets USP 50 mg

30

LOP17028C

Sep-19

31722-701-30

Losartan Potassium Tablets USP 50 mg

30

LOP17064A

Nov-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17027

Sep-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17063

Nov-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17093

Nov-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17094

Dec-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17095

Dec-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17097A

Dec-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17105

Dec-19

31722-701-90

Losartan Potassium Tablets USP 50 mg

90

LOP17107

Dec-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17004

Dec-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17028B

Sep-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17048

Oct-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17049

Oct-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17056

Nov-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17073

Nov-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17074

Nov-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17076

Nov-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP17096

Dec-19

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18077A

Feb-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18078

Feb-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18079

Feb-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18080

Feb-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18081

Mar-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18084

Mar-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18095

Mar-20

31722-701-10

Losartan Potassium Tablets USP 50 mg

1000

LOP18096

Mar-20

31722-702-30

Losartan Potassium Tablets USP 100 mg

30

LOP17011

Aug-19

31722-702-30

Losartan Potassium Tablets USP 100 mg

30

LOP17087

Nov-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP17012

Aug-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP17013

Aug-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP17042

Oct-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP17043

Oct-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP17044

Nov-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP17045

Nov-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18024

Dec-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18025

Dec-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18026

Dec-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18027

Dec-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18028

Dec-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18029

Dec-19

31722-702-90

Losartan Potassium Tablets USP 100 mg

90

LOP18030

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17005

May-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17014

Aug-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17016

Sep-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17023

Sep-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17083

Oct-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17084

Nov-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17085

Nov-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP17086

Nov-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18021

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18022

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18023

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18031

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18032

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18033

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18050

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18051

Dec-19

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18109

Mar-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18111

Mar-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18122

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18123

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18124

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18125

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18126

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18127

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18128

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18129

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18130

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18131C

Jun-20

31722-702-10

Losartan Potassium Tablets USP 100 mg

1000

LOP18133

Jun-20

Losartan Potassium Tablets were distributed Nationwide to Wholesalers, Distributors, Retail Pharmacies, and Mail Order Pharmacies.

Stericycle is notifying Camber's distributors and other customers by recall letter and arranging for return of recalled product of Losartan Potassium Tablets.

Consumers should contact their doctor for further guidance and potential change of treatment before they stop taking the product. Pharmacies and healthcare facilities that have the product being recalled should stop using and dispensing the product immediately.

Consumers with questions regarding this recall can contact Camber Pharmaceuticals' Med Line at 1-866-495-1995 Monday – Friday, 9am – 5pm EST. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax.

  • Complete and submit the report Online: www.fda.gov/medwatch/report.htm
  • Regular Mail or Fax: Download form www.fda.gov/MedWatch/getforms.htm or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178.

This recall is being conducted with the knowledge of the U.S. Food and Drug administration.

SOURCE Camber Pharmaceuticals

Related Links

http://www.camberpharma.com

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

icon3
440k+
Newsrooms &
Influencers
icon1
9k+
Digital Media
Outlets
icon2
270k+
Journalists
Opted In
GET STARTED

Modal title

Contact PR Newswire

  • Call PR Newswire at 888-776-0942
    from 8 AM - 9 PM ET
  • Chat with an Expert
  • General Inquiries
  • Editorial Bureaus
  • Partnerships
  • Media Inquiries
  • Worldwide Offices

Products

  • For Marketers
  • For Public Relations
  • For IR & Compliance
  • For Agency
  • All Products

About

  • About PR Newswire
  • About Cision
  • Become a Publishing Partner
  • Become a Channel Partner
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Italy
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United Kingdom
  • Vietnam

My Services

  • All New Releases
  • Platform Login
  • ProfNet
  • Data Privacy

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Platform Login
  • ProfNet
Call PR Newswire at
888-776-0942
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookies
Copyright © 2025 Cision US Inc.